A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers
NCT03647670
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
- Healthy female subjects and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive
- Female subjects with child-bearing potential must not be intending to become pregnant, currently pregnant, or lactating. Conditions apply: negative pregnancy test, effective method of contraception
- Non-childbearing potential must meet at least 1 of the following criteria: documented hysterectomy and/or bilateral oophorectomy, ovarian failure, achieved postmenopausal status confirmed with FSH
- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, GI, CV, hepatic, psych, neurological, or allergic disease (including drug
allergies, but excluding seasonal)
- Evidence or history of clinically significant dermatological condition (eg, contact
dermatitis or psoriasis) or visible rash present during physical examination
- Subjects, who according to the product label for midazolam, would be at increased risk
if dosed with midazolam
- Self-reported history or risk factors for QT prolongation or torsades de pointes,
congenital deafness, family history of sudden death, and family history of long QT
syndrome
- Any condition possibly affecting drug absorption (eg, gastrectomy)
- A positive urine drug test
- History of regular alcohol consumption exceeding 14 for female or 21 for male
drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard
liquor) within 6 months of screening
- Treatment with an investigational drug within 30 days (or as determined by the local
requirement) or 5 half-lives preceding the first dose of investigational product
(whichever is longer)
- Following at least 5 minutes of supine rest, screening supine systolic BP <90 mm Hg or
>=140 mm Hg, or screening supine diastolic BP <50 mm Hg or >=90 mm Hg. Any criteria
met, BP should be repeated
- Screening supine 12-lead ECG demonstrating: QTcF >450 msec or QRS interval >120 msec.
If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated
- AST/SGOT or ALT/SGPT >=1.5 × ULN. Total bilirubin level >1× ULN; subjects with a hx of
Gilbert's syndrome must have direct bilirubin <= ULN Known relevant history of
elevated liver function tests (LFTs)
- History of tuberculosis (TB) (active or latent) or inadequately treated TB infection.
Positive QuantiFERON® - TB Gold test
- Any history of chronic infections, any history of recurrent infections, any history of
latent infections, or any acute infection within 2 weeks of baseline
- History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent
localized dermatomal herpes zoster
- History of sensitivity to heparin or heparin-induced thrombocytopenia
- Pregnant or breastfeeding female; fertile male and WOCBP unwilling to use a highly
effective method of contraception through study duration and for at least 28 days
after the last dose
- Use of medications and dietary supplements within 7 days or 5 half-lives prior to
first dose, acetaminophen/paracetamol <=1 g/day exception. Herbal supplements and
hormonal methods of contraception
- Use of tobacco- or nicotine- containing products in excess of the equivalent of 5
cigarettes per day
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
within 60 days prior to first dose of investigational product
- History of hypersensitivity to midazolam or any other bezodiazapine
- History of HIV, hepatitis B or C; positive testing for HIV, HepBsAg, HepBcAb or HCVAb.
As an exception, a positive HepBsAb as a result of subject vaccination is permissible
- Unwilling or unable to comply with the criteria in the Lifestyle Requirements section
of this protocol
- Investigator site staff members and their family members, site staff members otherwise
supervised by the investigator, or subjects who are Pfizer employees, including their
family members
- Other medical or psych condition including active suicidal ideation/ behavior or lab
abnormality that the investigator deems inappropriate for this study or may interfere
with study results
- Have any malignancies or have a history of malignancies with the exception of
adequately treated or excised non-metastatic basal cell or squamous cell cancer of the
skin, or cervical carcinoma in situ
- Subjects at significant risk of suicidal or violent behavior
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Brussels,
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title ICMJE | A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers | ||||
Official Title ICMJE | A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, MULTIPLE DOSE, OPEN LABEL STUDY OF THE EFFECT OF PF-04965842 ON MIDAZOLAM PHARMACOKINETICS IN HEALTHY VOLUNTEERS | ||||
Brief Summary | This is a Phase 1, randomized, 2-way crossover, multiple dose, open label study of the effect of PF-04965842 on midazolam PK in healthy subjects. The study will demonstrate the effect of multiple dose PF-04965842 on the pharmacokinetics of a single, oral dose of midazolam in healthy subjects. | ||||
Detailed Description | Subjects will be randomized to 1 of 2 treatment sequences as described below. A total of 24 healthy male and/or female subjects will be enrolled in the study so that 12 subjects will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods in a single fixed sequence. Subjects will be screened within 28 days of the first dose of study medication. Subjects will report to the clinical research unit (CRU) the day prior to (or Day -1) Day 1 dosing in Period 1 for both treatment sequences. In Sequence 1 subjects will remain in the CRU for a total of 11 days and 10 nights (including Period 1 and Period 2). In Sequence 2, Period 1, subjects will remain in the CRU for 9 days and 8 nights. In Sequence 2, Period 2, subjects will remain in the CRU for 3 days and 2 nights. In Sequence 1, Period 1, subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hours (hr). Period 1 will be immediately followed by Period 2 with no washout, in which subjects will be dosed with 200 mg PF-04965842 orally once daily (QD) for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing.In Sequence 2, Period 1, subjects will be dosed with 200 mg PF-04965842 orally QD for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing. Subjects will then undergo a washout period of at least 7 days. In Period 2 subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hr. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Intervention Model Description: Natural log transformed area under the curve from zero to infinity, area under the plasma concentration-time curve from 0 to the time of last measurement and max plasma concentration of midazolam will be analyzed using a mixed effect model with sequence, period and treatment as fixed effects and subject within sequence as a random effect. Estimates of the adj mean differences (Test-Reference) and corresponding 90% CIs will be obtained from the model. The adjusted mean differences and 90% CIs for the differences will be exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% confidence intervals for the ratios. Midazolam alone will be the Reference treatment, while the midazolam co-administered with PF-04965842 will be the Test treatment. The lack of an effect of PF-04965842 on midazolam PK will be concluded if the 90% CI for the ratio of adjusted geometric mean for AUCinf falls wholly within acceptance region (80%, 125%). Masking: None (Open Label)Primary Purpose: Other | ||||
Condition ICMJE | Phase 1 | ||||
Intervention ICMJE |
| ||||
Study Arms ICMJE |
| ||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE | 25 | ||||
Original Estimated Enrollment ICMJE | 24 | ||||
Actual Study Completion Date ICMJE | October 16, 2018 | ||||
Actual Primary Completion Date | October 16, 2018 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||
Sex/Gender ICMJE |
| ||||
Ages ICMJE | 18 Years to 55 Years (Adult) | ||||
Accepts Healthy Volunteers ICMJE | Yes | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Belgium | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03647670 | ||||
Other Study ID Numbers ICMJE | B7451022 2018-001198-26 ( EudraCT Number ) | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
| ||||
IPD Sharing Statement ICMJE |
| ||||
Responsible Party | Pfizer | ||||
Study Sponsor ICMJE | Pfizer | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
| ||||
PRS Account | Pfizer | ||||
Verification Date | March 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |